Overview

This trial is active, not recruiting.

Conditions acquired immunodeficiency syndrome, hiv infections
Treatments e/c/f/taf, e/c/f/tdf, placebo to match e/c/f/taf, placebo to match e/c/f/tdf
Phase phase 2
Sponsor Gilead Sciences
Start date December 2011
End date October 2012
Trial size 150 participants
Trial identifier NCT01497899, GS-US-292-0102

Summary

This study is to evaluate the safety, efficacy, and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) versus E/C/F/tenofovir disoproxil fumarate (TDF; E/C/F/TDF) STR in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
Participants will receive E/C/F/TAF plus placebo to match E/C/F/TDF.
e/c/f/taf
Elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/GS-7340 10mg STR administered orally once daily
placebo to match e/c/f/tdf
Placebo to match E/C/F/TDF administered orally once daily
(Active Comparator)
Participants will receive E/C/F/TDF plus placebo to match E/C/F/TAF.
e/c/f/tdf
Elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/ tenofovir disoproxil fumarate 300 mg STR administered orally once daily
placebo to match e/c/f/taf
Placebo to match E/C/F/TAF administered orally once daily

Primary Outcomes

Measure
Percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24
time frame: Week 24

Secondary Outcomes

Measure
Percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48
time frame: Week 48
Change from baseline in log10 HIV-1 RNA and in CD4+ cell count at Weeks 24 and 48
time frame: Weeks 24 and 48
Percentage of participants switching from a cobicistat-boosted darunavir regimen that remain suppressed at Week 48 of the open-label extension phase
time frame: Week 48

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Ability to understand and sign a written informed consent form - Plasma HIV 1 RNA levels ≥ 5,000 copies/mL - No prior use of any approved or experimental anti-HIV drug for any length of time - Screening genotype report must show sensitivity to TDF and emtricitabine (FTC) - Normal ECG - Adequate renal function: Estimated glomerular filtration rate ≥ 70 mL/min according to the Cockcroft Gault formula - Hepatic transaminases ≤ 2.5 x upper limit of the normal range (ULN) - Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin - Adequate hematologic function - CD4+ cell count > 50 cells/µL - Serum amylase ≤ 5 x ULN - Normal thyroid-stimulating hormone (TSH) - Females of childbearing potential must have a negative serum pregnancy test - Females of childbearing potential must agree to utilize highly effective contraception methods from screening throughout the duration of study treatment and for 30 days following the last dose of study drugs - Female subjects who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing - Female subjects who are postmenopausal must have documentation of cessation of menses for ≥ 12 months and hormonal failure - Female subjects who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level test at screening - Male subjects must agree to utilize a highly effective method of contraception during heterosexual intercourse throughout the study period and for 90 days following discontinuation of investigational medicinal product - Age ≥ 18 years - Life expectancy ≥ 1 year Exclusion Criteria: - New AIDS-defining condition diagnosed within the 30 days prior to screening - Hepatitis B surface Antigen positive - Hepatitis C Antibody positive - Proven acute hepatitis in the 30 days prior to study entry - Subjects experiencing decompensated cirrhosis - Females who are breastfeeding - Positive serum pregnancy test (female of childbearing potential) - Have an implanted defibrillator or pacemaker - Receiving ongoing therapy with any of the disallowed medications, including drugs not to be used with elvitegravir and cobicistat - Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents or systemic steroids during the study - Current alcohol or substance - History of or ongoing malignancy (including untreated carcinoma in-situ) other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma or resected, non-invasive cutaneous squamous carcinoma - Active, serious infections (other than HIV 1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Baseline - Participation in any other clinical trial without prior approval is prohibited while participating in this trial - Medications contraindicated for use with emtricitabine or tenofovir disoproxil fumarate - Any known allergies to the excipients of E/C/F/TAF or E/C/F/TDF STR tablets - Any other clinical condition or prior therapy that would make the subject unsuitable for the study or unable to comply with the dosing requirements

Additional Information

Official title A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
Trial information was received from ClinicalTrials.gov and was last updated in June 2014.
Information provided to ClinicalTrials.gov by Gilead Sciences.